Radiother Oncol 2020 Jul 31
An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib.
ABSTRACT
Our study is the first to report an especially high rate of grade 2 or worse radiation pneumonitis in patients treated with thoracic radiotherapy and simultaneous Osimertinib, despite total lung V5, V20 and MLD seeming unlikely to induce radiation pneumonitis.
Related Questions
Does the site of treatment factor into your decision?
New answer by Radiation Oncologist at Wake Forest School of Medicine (July 13, 2021)
As far as I know, there is not a clear answer for this situation. After discussion with our medical oncology team, we currently tend to hold osimertinib for about 5-7 days pri...